Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions

PURPOSE: Studies were conducted to investigate dilute solutions of the monoclonal antibody (mAb) bevacizumab, mAb fragment ranibizumab and fusion protein aflibercept, develop common procedures for formulation of low concentration mAbs and identify a stabilizing formulation for anti-VEGF mAbs for use...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannos, Steven A., Kraft, Edward R., Zhao, Zhen-Yang, Merkley, Kevin H., Cai, Jiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830485/
https://www.ncbi.nlm.nih.gov/pubmed/29492680
http://dx.doi.org/10.1007/s11095-018-2368-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830485/
https://www.ncbi.nlm.nih.gov/pubmed/29492680
http://dx.doi.org/10.1007/s11095-018-2368-7

Ejemplares similares